|
Post by goyocafe on Jan 11, 2021 11:00:27 GMT -5
and it sounds like the India Trial has startet... did i hear it right? You heard that right. PRs must have been eliminated as part of MNKDs overall cost cutting measures.
|
|
|
Post by brentie on Jan 11, 2021 12:01:25 GMT -5
|
|
|
Post by buyitonsale on Jan 11, 2021 17:42:31 GMT -5
Around 16:53 mark in the recording... "So I think that's a lot of the incentive to get this filed and get this moving ASAP. So that later this year, we'll be launching this product" That is all I needed to hear
|
|
|
Post by lennymnkd on Jan 11, 2021 18:01:30 GMT -5
And ; MIKE .. So we're excited when you think about pedes this year, Afrezza growth, TreT growth, Thyquidity you know, co promote, and Qrum moving into Phase I. So MannKind's got a lot there. And I still have a couple other things to do 🤔👍
|
|
|
Post by obamayoumama on Jan 11, 2021 19:51:02 GMT -5
|
|
|
Post by georgethenight2 on Jan 11, 2021 20:52:04 GMT -5
Trep-T sales could hit the books this year, combined with MNKD's historically low cash burn of $13m a quarter, dare I say profitability is less than 12 months away. Combined with Afrezza's current trend of increasing sales, we might be treading in foreign territory, a cash flow positive company. Wow!
And a question about MC's chat, he stated that Indian trials have begun, but in the same breathe he included Brazil, what did he mean by Brazil? The drug is already approved their, correct? 13:25-
Finally, during the chat, Oren stated that the "possible" sales for Trep-T could be a 10x situation. From current patient numbers of 2000-3000, to over 100,000. This could be a $100,000,000/year opportunity for MNKD, no?
|
|
|
Post by Chris-C on Jan 14, 2021 15:41:35 GMT -5
And ; MIKE .. So we're excited when you think about pedes this year, Afrezza growth, TreT growth, Thyquidity you know, co promote, and Qrum moving into Phase I. So MannKind's got a lot there. And I still have a couple other things to do 🤔👍 Hmmm...so I guess we can assume that there are a couple of "irons in the fire" that cannot yet be announced. Is this tantalizing CEO speak, or something that could be significant? Time will tell. Meantime, It's hard not to share MC's excitement with the list of things going on. Now, if we just had an extra $100 million to see us into the royalties from Tyvaso DPI and free up some operating capital after discharging the loan covenants. (Sigh) Let's hope to pass the long awaited 1000 weekly script threshold in the first quarter. It might not move the market, but it will be significant to longsuffering longs. GLTAL
|
|
|
Post by jlaw277 on Jan 14, 2021 20:03:34 GMT -5
And ; MIKE .. So we're excited when you think about pedes this year, Afrezza growth, TreT growth, Thyquidity you know, co promote, and Qrum moving into Phase I. So MannKind's got a lot there. And I still have a couple other things to do 🤔👍 Hmmm...so I guess we can assume that there are a couple of "irons in the fire" that cannot yet be announced. Is this tantalizing CEO speak, or something that could be significant? Time will tell. Meantime, It's hard not to share MC's excitement with the list of things going on. Now, if we just had an extra $100 million to see us into the royalties from Tyvaso DPI and free up some operating capital after discharging the loan covenants. (Sigh) Let's hope to pass the long awaited 1000 weekly script threshold in the first quarter. It might not move the market, but it will be significant to longsuffering longs. GLTAL MC says that the pediatric trials will begin in Q1/Q2 2021. At least I believe he says that in the Wainwright chat. Do they require a partner for this trial? It must be fairly expensive being a Phase 3. If he is speaking about a timetable for the trial, can we infer that there probably is a partner involved?
|
|
|
Post by goyocafe on Jan 14, 2021 20:16:10 GMT -5
Hmmm...so I guess we can assume that there are a couple of "irons in the fire" that cannot yet be announced. Is this tantalizing CEO speak, or something that could be significant? Time will tell. Meantime, It's hard not to share MC's excitement with the list of things going on. Now, if we just had an extra $100 million to see us into the royalties from Tyvaso DPI and free up some operating capital after discharging the loan covenants. (Sigh) Let's hope to pass the long awaited 1000 weekly script threshold in the first quarter. It might not move the market, but it will be significant to longsuffering longs. GLTAL MC says that the pediatric trials will begin in Q1/Q2 2021. At least I believe he says that in the Wainwright chat. Do they require a partner for this trial? It must be fairly expensive being a Phase 3. If he is speaking about a timetable for the trial, can we infer that there probably is a partner involved? You’d think we’d hear about the Phase II results before Phase III starts, so maybe that can be a more accurate starting point.
|
|
|
Post by letitride on Jan 14, 2021 20:37:47 GMT -5
Considering there was no PR on CIPLA not everything happening with Mannkind is common knowledge. My Guess is proprietary knowledge is no longer freely available, and held close for better execution. Something of a surprise party the shorts should consider.
|
|
|
Post by longliner on Jan 14, 2021 23:53:26 GMT -5
Considering there was no PR on CIPLA not everything happening with Mannkind is common knowledge. My Guess is proprietary knowledge is no longer freely available, and held close for better execution. Something of a surprise party the shorts should consider. They certainly deserve a surprise party.
|
|